Nifty
Sensex
:
:
14677.80
48732.55
-18.70 (-0.13%)
41.75 (0.09%)

Pharmaceuticals & Drugs

Rating :
63/99

BSE: 526953 | NSE: VENUSREM

312.45
14-May-2021
  • Open
  • High
  • Low
  • Previous Close
  •  315.50
  •  328.85
  •  308.15
  •  315.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  49318
  •  156.65
  •  353.75
  •  43.45

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 385.56
  • 18.12
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 603.89
  • N/A
  • 1.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 35.89%
  • 4.24%
  • 54.71%
  • FII
  • DII
  • Others
  • 0.04%
  • 0.00%
  • 5.12%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.61
  • -3.98
  • -2.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -7.61
  • -12.84
  • 0.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -31.19

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.07
  • 9.32
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.36
  • 0.26
  • 0.27

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.10
  • 7.09
  • 8.25

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
121.94
96.86
25.89%
126.07
87.89
43.44%
188.75
73.65
156.28%
83.06
90.44
-8.16%
Expenses
103.86
86.06
20.68%
115.42
75.19
53.50%
173.19
63.86
171.20%
75.53
88.89
-15.03%
EBITDA
18.08
10.79
67.56%
10.65
12.71
-16.21%
15.55
9.78
59.00%
7.53
1.56
382.69%
EBIDTM
14.83%
11.14%
8.45%
14.46%
8.24%
13.28%
9.07%
1.72%
Other Income
1.83
1.77
3.39%
12.28
1.35
809.63%
2.04
0.82
148.78%
3.18
4.29
-25.87%
Interest
1.81
4.07
-55.53%
7.39
4.91
50.51%
2.85
6.18
-53.88%
0.00
0.00
0
Depreciation
8.70
8.48
2.59%
8.61
8.56
0.58%
3.59
8.50
-57.76%
6.47
8.46
-23.52%
PBT
13.86
0.02
69,200.00%
14.52
0.58
2,403.45%
1.97
-4.07
-
-4.56
-11.57
-
Tax
2.21
0.99
123.23%
1.49
0.16
831.25%
0.00
0.00
0
0.82
-0.10
-
PAT
11.65
-0.96
-
13.03
0.42
3,002.38%
1.97
-4.07
-
-5.38
-11.46
-
PATM
9.56%
-0.99%
10.33%
0.47%
1.05%
-5.53%
-6.48%
-12.68%
EPS
9.44
-0.78
-
10.55
0.34
3,002.94%
1.60
-3.30
-
-4.36
-9.29
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
519.82
341.46
321.89
372.41
400.04
418.27
463.99
541.56
468.64
409.84
363.09
Net Sales Growth
49.01%
6.08%
-13.57%
-6.91%
-4.36%
-9.85%
-14.32%
15.56%
14.35%
12.88%
 
Cost Of Goods Sold
299.82
174.31
181.95
205.08
227.07
238.51
268.94
300.00
262.26
225.91
201.50
Gross Profit
220.00
167.15
139.94
167.33
172.97
179.77
195.05
241.55
206.38
183.92
161.59
GP Margin
42.32%
48.95%
43.47%
44.93%
43.24%
42.98%
42.04%
44.60%
44.04%
44.88%
44.50%
Total Expenditure
468.00
300.64
289.37
332.94
349.32
337.11
374.81
403.33
348.53
306.96
273.00
Power & Fuel Cost
-
4.73
4.86
4.29
4.14
4.01
3.80
3.38
3.05
2.71
2.72
% Of Sales
-
1.39%
1.51%
1.15%
1.03%
0.96%
0.82%
0.62%
0.65%
0.66%
0.75%
Employee Cost
-
46.02
42.10
39.31
34.27
32.44
32.36
30.45
27.30
24.83
20.38
% Of Sales
-
13.48%
13.08%
10.56%
8.57%
7.76%
6.97%
5.62%
5.83%
6.06%
5.61%
Manufacturing Exp.
-
20.84
21.01
36.10
42.48
15.70
17.29
22.10
20.61
18.18
17.05
% Of Sales
-
6.10%
6.53%
9.69%
10.62%
3.75%
3.73%
4.08%
4.40%
4.44%
4.70%
General & Admin Exp.
-
17.57
11.85
13.52
13.26
11.97
15.67
14.74
11.82
12.14
11.54
% Of Sales
-
5.15%
3.68%
3.63%
3.31%
2.86%
3.38%
2.72%
2.52%
2.96%
3.18%
Selling & Distn. Exp.
-
37.18
27.60
34.65
28.10
34.48
36.75
32.65
23.50
22.98
19.82
% Of Sales
-
10.89%
8.57%
9.30%
7.02%
8.24%
7.92%
6.03%
5.01%
5.61%
5.46%
Miscellaneous Exp.
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.20
19.82
% Of Sales
-
0%
0%
0%
0%
0%
0%
0%
0%
0.05%
0%
EBITDA
51.81
40.82
32.52
39.47
50.72
81.16
89.18
138.23
120.11
102.88
90.09
EBITDA Margin
9.97%
11.95%
10.10%
10.60%
12.68%
19.40%
19.22%
25.52%
25.63%
25.10%
24.81%
Other Income
19.33
5.31
6.09
2.39
4.28
2.01
0.68
0.47
0.44
0.49
0.40
Interest
12.05
13.34
25.41
35.56
36.38
37.98
41.21
29.40
24.63
27.49
18.86
Depreciation
27.37
32.01
33.98
33.83
40.26
41.68
46.00
40.22
33.08
25.02
18.98
PBT
25.79
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
62.84
50.85
52.63
Tax
4.52
1.96
-1.15
3.16
-4.56
1.81
-2.51
4.78
5.53
3.78
6.41
Tax Rate
17.53%
-24.41%
3.87%
-11.48%
21.07%
51.57%
-94.72%
6.92%
8.80%
7.43%
12.18%
PAT
21.27
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
57.31
47.08
46.22
PAT before Minority Interest
21.27
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
57.31
47.08
46.22
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
4.09%
-2.93%
-8.88%
-8.24%
-4.27%
0.41%
1.11%
11.87%
12.23%
11.49%
12.73%
PAT Growth
232.36%
-
-
-
-
-67.05%
-91.98%
12.20%
21.73%
1.86%
 
EPS
17.29
-8.13
-23.23
-24.95
-13.89
1.38
4.20
52.28
46.59
38.28
37.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
323.37
332.52
361.91
388.67
437.62
456.68
461.61
379.13
307.29
236.92
Share Capital
12.34
12.34
12.34
12.34
11.44
11.44
11.44
10.54
9.74
9.13
Total Reserves
311.03
320.18
349.57
376.33
426.18
445.24
450.17
363.81
288.53
223.59
Non-Current Liabilities
95.82
136.68
158.47
179.52
212.05
221.55
161.75
147.18
113.51
99.41
Secured Loans
24.19
61.29
86.60
112.69
134.57
150.95
114.76
103.89
75.45
65.97
Unsecured Loans
47.87
54.73
50.84
49.13
56.47
51.34
25.22
25.22
23.68
22.02
Long Term Provisions
6.63
5.32
4.50
4.29
3.79
3.78
3.31
2.91
2.50
1.94
Current Liabilities
218.53
263.62
230.38
196.81
193.14
162.83
210.99
191.25
153.22
124.53
Trade Payables
36.70
36.00
29.33
29.73
25.14
29.56
31.22
18.76
12.55
7.02
Other Current Liabilities
95.65
110.30
78.47
46.16
42.71
15.96
54.70
58.18
43.44
40.07
Short Term Borrowings
85.58
112.80
121.26
119.16
123.32
115.40
110.08
95.68
83.24
63.17
Short Term Provisions
0.61
4.52
1.32
1.76
1.97
1.91
14.99
18.63
13.99
14.27
Total Liabilities
637.72
732.82
750.76
765.00
842.81
841.06
834.35
717.56
574.02
460.86
Net Block
289.37
364.45
389.20
406.18
452.48
443.65
439.46
401.42
355.39
293.28
Gross Block
623.96
707.02
702.77
686.50
679.57
641.12
587.38
511.00
430.25
343.15
Accumulated Depreciation
334.59
342.57
313.57
280.32
227.09
197.47
147.93
109.58
74.87
49.86
Non Current Assets
349.77
467.39
490.50
505.60
565.75
607.85
562.24
491.97
404.40
322.49
Capital Work in Progress
24.63
64.76
64.76
66.25
80.37
78.30
67.80
47.81
23.00
15.31
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
35.77
38.18
36.53
33.17
32.90
85.91
54.98
42.74
26.01
13.91
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
287.95
265.43
260.27
259.41
277.07
233.21
272.11
225.58
169.63
138.37
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
141.12
142.73
138.17
140.60
143.29
142.87
142.26
128.03
96.82
75.43
Sundry Debtors
30.69
38.04
47.27
47.29
61.59
63.22
64.99
47.11
40.10
35.74
Cash & Bank
2.13
2.81
3.98
3.56
7.07
3.62
4.41
6.36
2.95
3.12
Other Current Assets
114.01
5.15
4.84
0.00
65.12
23.51
60.47
44.08
29.77
24.07
Short Term Loans & Adv.
58.29
76.70
66.00
67.96
65.12
23.51
60.47
44.08
29.77
23.87
Net Current Assets
69.43
1.81
29.88
62.59
83.93
70.38
61.12
34.33
16.41
13.84
Total Assets
637.72
732.82
750.77
765.01
842.82
841.06
834.35
717.55
574.03
460.86

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
77.01
45.33
31.19
58.93
46.88
67.80
52.65
52.15
41.67
37.35
PBT
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
62.84
50.85
52.63
Adjustment
41.56
60.72
66.24
70.61
56.41
83.56
37.21
40.72
29.96
24.74
Changes in Working Capital
20.23
5.37
-7.52
9.96
-13.04
-18.40
-53.65
-51.41
-39.14
-40.02
Cash after chg. in Working capital
62.57
45.33
31.19
58.93
46.88
67.80
52.65
52.15
41.67
37.35
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
14.44
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4.75
-11.33
-11.48
-18.32
2.92
-67.18
-94.66
-103.89
-95.15
-96.43
Net Fixed Assets
124.42
-5.05
-11.74
18.95
-50.18
-67.39
-93.77
-101.63
-93.38
-94.69
Net Investments
0.00
0.00
28.60
0.00
0.00
0.00
0.00
0.00
-0.37
-3.58
Others
-129.17
-6.28
-28.34
-37.27
53.10
0.21
-0.89
-2.26
-1.40
1.84
Cash from Financing Activity
-73.00
-35.17
-39.23
-44.13
-46.35
-1.42
40.06
55.15
53.31
59.80
Net Cash Inflow / Outflow
-0.74
-1.17
-19.52
-3.51
3.46
-0.79
-1.95
3.41
-0.17
0.72
Opening Cash & Equivalents
2.81
3.98
0.00
7.07
3.62
4.41
6.36
2.95
3.12
2.40
Closing Cash & Equivalent
2.13
2.81
-19.52
3.56
7.07
3.62
4.41
6.36
2.95
3.12

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
262.01
269.42
293.23
314.92
382.47
399.13
403.43
355.10
306.18
254.92
ROA
-1.46%
-3.85%
-4.05%
-2.12%
0.20%
0.62%
8.29%
8.87%
9.10%
11.40%
ROE
-3.05%
-8.23%
-8.18%
-4.13%
0.38%
1.12%
15.38%
17.04%
17.73%
23.07%
ROCE
0.90%
-0.67%
1.17%
2.00%
5.35%
5.74%
14.06%
14.85%
16.47%
19.24%
Fixed Asset Turnover
0.51
0.46
0.54
0.59
0.63
0.76
0.99
1.00
1.06
1.20
Receivable days
36.73
48.37
46.34
49.67
54.45
50.42
37.72
33.88
33.71
32.14
Inventory Days
151.71
159.26
136.61
129.51
124.86
112.15
90.94
87.34
76.56
68.94
Payable days
42.53
37.91
30.30
26.74
26.74
27.25
21.28
15.09
11.03
8.63
Cash Conversion Cycle
145.91
169.72
152.65
152.44
152.57
135.32
107.37
106.14
99.25
92.44
Total Debt/Equity
0.68
0.90
0.85
0.80
0.77
0.70
0.63
0.72
0.74
0.80
Interest Cover
0.40
-0.17
0.23
0.41
1.09
1.06
3.35
3.55
2.85
3.79

News Update:


  • Venus Remedies partners with West Pharmaceutical Services to launch Cloti-Xa in India
    13th Apr 2021, 13:33 PM

    Cloti-Xa which contains enoxaparin sodium is being introduced with added advantage of NovaGuard SA Pro safety system

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.